Jubilant Pharmova Limited Overview
Jubilant Pharmova is an India-domiciled, North America-centric specialty pharmaceutical and pharmaceutical-services group that has deliberately abandoned commodity chemistry in favour of high-barrier, licence-protected niches. Roughly 81% of revenue originates in the United States and 94% is denominated in US dollars — an unusual profile for an Indian mid-cap. Its economic core is radiopharmaceuticals: it is a leading North American manufacturer of SPECT diagnostic agents, operates the second-largest US radiopharmacy network (45 sites serving c.1,800 hospitals), holds a monopoly position in Iodine-131 for thyroid indications, and is the innovation leader in Rubidium-82 cardiac PET through Ruby-Fill. Adjacent to this sit the second-largest US allergenic-extract franchise (sole domestic venom supplier), a fast-scaling sterile-injectables CDMO at Spokane, Washington, an integrated Indian CRDMO, a rebuilt generics business, and an early-clinical oncology pipeline. The investment question is execution: capability is not in doubt; conversion of heavy capital deployment into returns, and durable FDA compliance, are.
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Global employees (approximate) | 5,100 | 5,400 | 5,500 |
Note: the company discloses headcount only as an approximate global figure ("approx. 5,500") in investor materials rather than as an audited year-end number. The FY2024 and FY2025 figures above are indicative reconstructions from successive investor presentations and third-party data aggregators (TipRanks records 5,399). Precise audited year-end headcount is not publicly disclosed in a consistent series.
The company's own characterisation
Jubilant Pharmova describes itself in its FY2026 disclosures as "a company with global presence that is involved in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics and Proprietary Novel Drugs businesses." Its investor materials position the group as "a diversified pharmaceutical company" with a stated strategic emphasis on "specialty products and services and Dollar revenues," operating six manufacturing facilities, three research facilities, and 45 radiopharmacies, serving over 50 countries including all major regulated markets, with a workforce of approximately 5,500. The group's stated corporate values — "Caring, Sharing, Growing" — are inherited from the wider Jubilant Bhartia Group.
Independent characterisation
The self-description understates the degree to which this is really two businesses with radically different economics stapled to a venture-stage third.
Business one — the specialty franchise (Radiopharmaceuticals, Allergy Immunotherapy). These are the profit engines. Radiopharmaceutical manufacturing carried a 44% EBITDA margin in FY2026 (47% in FY2025, 50% in FY2024); Allergy Immunotherapy carried 35%. Both are protected by structural moats that have little to do with patents: radioactive isotopes decay on a timescale of hours to days, so the business is really a just-in-time logistics business wrapped around a nuclear licence. Every treatment site requires a Nuclear Regulatory Commission licence plus state, local and hospital-level approvals; authorised nuclear pharmacists require at least 4,000 hours of specialist training. Allergenic extracts sit behind an even odder moat: most of the portfolio operates under grandfathered approvals, any genuinely new product requires a Biologics License Application, and the US subcutaneous immunotherapy market has consolidated to three players. Jubilant is the sole US supplier of venom immunotherapy extracts.
Business two — the services franchise (CDMO Sterile Injectables, CRDMO). These are capital-hungry, margin-thinner, but currently growing fastest. Sterile fill-and-finish is a capacity business: contracts typically run three years or more with auto-renewal, technology transfer takes 18–24 months, switching costs are consequently very high, and 90%+ of business is repeat. Jubilant counts 5 of the top 20 global pharmaceutical companies as customers and reports a 92% customer retention rate. The Indian CRDMO arm (Jubilant Biosys) sells scientist-hours and process chemistry, with 8 of the top 20 pharma companies as clients and 85+ integrated discovery programmes delivered.
Business three — Proprietary Novel Drugs (Jubilant Therapeutics). Pre-revenue, cash-consuming (roughly ₹16 crore of EBITDA loss in FY2026), and optionality-driven.
Revenue model. Overwhelmingly product sales and manufacturing services, not licensing or subscription. Approximately 54% of FY2026 revenue was product sales (radiopharmaceuticals, radiopharmacy compounded doses, allergenic extracts, generic formulations, APIs) and approximately 36% was contract manufacturing and research services. There is essentially no royalty, milestone or subscription revenue today; the Proprietary Novel Drugs unit has explicitly stated it will "explore monetization through licensing or external fund raising," which would introduce a licensing revenue line for the first time.
Value chain position. Unusually, Jubilant occupies both the manufacturing and distribution rungs in radiopharma. It manufactures the radiopharmaceutical (Kirkland/Montreal, Canada) and compounds and distributes patient-ready doses through its own radiopharmacy network and fleet. This forward integration is the single most important structural feature of the company: it converts a product-manufacturing margin into a manufacturing-plus-distribution margin and gives the company channel control over hospital customers.
Customer types and end-markets. Hospitals, imaging centres and cardiology practices (radiopharma; c.1,800 hospitals served); allergists and ENT specialists (c.2,000 US practitioners); innovator pharmaceutical and biotechnology companies (CDMO and CRDMO); generic distributors, wholesalers and B2B2C partners in 50+ markets (generics). End-markets served: oncology diagnostics and therapy, cardiology, nephrology, pulmonology, endocrinology, allergy and immunology, cardiovascular, CNS, gastrointestinal and multi-specialty generics.
Strategy
Vision 2030 — the stated strategic frame
| Target | FY2024 actual | FY2030 target | Latest actual |
|---|---|---|---|
| Revenue (INR Cr) | 6,703 | 13,500 | 8,280 |
| EBITDA margin (%) | 15 | 24 | 16 |
| Net debt (INR Cr) | 2,457 | 0 | 1,751 |
| Return on capital employed | High single digit | High teens | High single digit |
Jubilant Pharmova's articulated strategy is a single named programme, Vision 2030, with four hard quantitative targets measured from an FY2024 base:
Latest actuals: revenue and EBITDA margin are FY2026; net debt is as at 31 December 2025 (FY2026 year-end net debt not separately disclosed); RoCE is 9M FY2026 annualised on the company's own definition.
To hit ₹13,500 crore by FY2030 from ₹8,280 crore in FY2026 requires a 13.0% revenue CAGR over four years — achievable given FY2026 delivered 14.5%, but demanding given the FY2022–FY2026 CAGR was 7.8%. The EBITDA margin target of 23–25% requires 700–900 basis points of expansion from the FY2026 level of 15.9%, which is the genuinely hard part of the plan.
Segment-level Vision 2030 commitments
| Business | FY2024 base revenue (INR Cr) | FY2030 revenue ambition | FY2030 EBITDA margin ambition |
|---|---|---|---|
| Radiopharmaceuticals | 952 | More than 2x FY2024 | More than 50% |
| Radiopharmacy | 2,050 | 2x FY2024 | 7% to 8% |
| Allergy Immunotherapy | 679 | Approximately 1.5x FY2024 | 35% to 40% |
| CDMO Sterile Injectables | 1,117 | More than 2x FY2024 | More than 25% |
| CRDMO Drug Discovery Services | 449 | Approximately 3x FY2024 | More than 25% |
| CRDMO CDMO-API | 645 | 2x FY2024 | More than 15% |
| Generics | 775 | Approximately 2x FY2024 | 15% to 17% |
The arithmetic of the group margin target is instructive: the largest single swing factor is Radiopharmacy moving from a 1% to a 7–8% margin on a doubled revenue base — worth roughly ₹300 crore of incremental EBITDA on its own. This is why the six-site PET expansion is disproportionately important to the equity story relative to its capital cost.
Announced strategic initiatives, last 24 months
Capacity and capital projects
-
Spokane Line 3 — US$132 million, isolator technology, +50% capacity, launched October 2025; one of the world's largest oncology products onboarded; commercial batch production late FY2027 subject to FDA approval; peak revenue potential US$80–90 million
-
Spokane Line 4 — installation completed Q1 FY2027; technology transfer revenue from Q4 FY2027; commercial production FY2028; peak revenue potential US$80–90 million. Lines 3 and 4 together carry combined potential of US$160–180 million
-
Montreal Line 5 (new isolator fill and finish line) — capex US$114 million with a US$35 million concessional loan; construction started, plant and machinery ordered; technology transfer revenue expected FY2029
-
PET radiopharmacy network expansion — US$50 million (later stated as US$60m+), from 3 to 9 sites, fully operational FY2028, funded through internal accruals and long-term credit; expected asset turnover 1.0x and RoCE above 20%
-
CRDMO capacity build — total capex US$150 million to take drug discovery from 1,000 FTEs (FY2025) to 2,000 (FY2028) to 4,000 (FY2030), including a new Devanahalli, Bengaluru site and expansions at Greater Noida and Bengaluru; expected RoCE above 20%
-
Jubilant Biosys Noida facility — opened January 2026, multimillion-dollar, doubles overall chemistry capacity for discovery research and scale-up, with two pilot plants, targeting fee-for-service demand
Structural and portfolio moves
-
API business transfer to Jubilant Biosys Limited — board approved 12 June 2025, completed FY2026. Rationale: house drug discovery and CDMO-API in a single entity; improve operational efficiency; build brand recall for "Jubilant Biosys" as an end-to-end CRDMO provider spanning drug discovery, early CDMO, late CDMO and commercial manufacturing; improve API asset utilisation by shifting mix toward custom manufacturing
-
Pierre Fabre strategic partnership (France) — added a Centre of Excellence in Biologics at St Julien; expands total addressable market by US$1.4 billion in mAbs and ADCs; adds EU footprint and ADC domain expertise; integration described as complete with investment now flowing into business development
Commercial initiatives
-
Pluvicto distribution — radiopharmacy network began distributing the leading prostate-cancer radioligand therapy during FY2026
-
Ga-68 PSMA market expansion — extended to 38 US markets
-
Ruby-Fill AI innovation — AI-enabled 3D cardiac blood flow quantification under development
-
Generics relaunch programme — 6–8 new products annually, relaunching dormant ANDAs from Roorkee and the CMO network, plus in-licensing and targeted ANDA acquisition
-
Alternate CMO development for key SPECT products, to de-risk the Montreal single-point dependency
-
FY2025 Sustainability Report published with EY assurance; sustainability-linked loan KPIs assured by EY; targets set for renewable power share, specific GHG emissions, and specific water consumption
Innovation and monetisation
- Proprietary Novel Drugs monetisation — management has explicitly stated it will "explore monetization through licensing or external fund raising," with clinical data readouts expected in CY2026; the appointment of Daniel J. O'Connor is consistent with preparing for this
Management's medium-term guidance
Management has been careful to avoid specific annual revenue or EPS guidance. The concrete forward statements are:
"We expect growth momentum to strengthen in FY27": - "EBITDA margins to strengthen from H2'FY27 onwards" post-stabilisation of Montreal production, "effectively offsetting higher depreciation costs and driving net profit growth"
-
Montreal operating losses expected to taper off in H2 FY2027; segment EBITDA breakeven at Montreal targeted FY2028
-
Full SPECT product availability expected H2 FY2027; batch releases from Q2 FY2027
-
Net debt to EBITDA to remain range-bound in the near term
-
"We expect to deliver healthy revenue growth and steady margins"
Products & Services
Radiopharmaceuticals (manufactured at Kirkland/Montreal, Canada; marketed as Jubilant Radiopharma / Jubilant DraxImage)
| Product | Isotope / modality | Indication | Positioning |
|---|---|---|---|
| Draximage® MAA (Macro Aggregated Albumin) | Tc-99m, SPECT | Perfusion phase of ventilation/perfusion (V/Q) scan for pulmonary embolism | Leading player in the US market |
| Draximage® DTPA (Diethylenetriaminepentaacetic acid) | Tc-99m, SPECT | Pulmonary ventilation function, used with MAA for V/Q scan | Leading player in the US market; faced generic entry during FY2026 |
| Technetium Tc-99m Sulfur Colloid Injection | Tc-99m, SPECT | Localisation of metastatic lymph nodes in breast cancer and melanoma; liver, spleen and bone marrow imaging; oesophageal transit, gastro-oesophageal reflux, detection of pulmonary aspiration | Core sentinel-node product |
| Tc-99m Mertiatide | Tc-99m, SPECT | Renal failure / renal function imaging | USFDA approval obtained FY2023; a key FY2024 growth driver |
| Tc-99m Gluceptate | Tc-99m, SPECT | Cardiac blood pool imaging | — |
| Tc-99m Sestamibi | Tc-99m, SPECT | Coronary artery disease | High-volume cardiac agent |
| Tc-99m Exametazime | Tc-99m, SPECT | Intra-abdominal infection (labelled leukocyte imaging) | — |
| Tc-99m MDP | Tc-99m, SPECT | Altered osteogenesis / bone scanning | — |
| RUBY-FILL® Rubidium Rb-82 Generator and RUBY® Rubidium Elution System | Rb-82, PET | Myocardial perfusion imaging at rest or under pharmacologic stress in suspected or existing coronary artery disease | Flagship. FDA approved 2016; mobile-use clearance received 2023. Addressable market c.US$180m growing at 12%; Jubilant share c.25% and rising. Competitive advantages: 7-week generator life versus 6 weeks for the peer product; constant activity; better image consistency; more scans per day than F-18 labelled agents; no incremental shielding capex. Install base grew 35% in FY2026 (21% in FY2025) and 26% YoY in Q1 FY2027. Product innovation underway in AI-enabled 3D cardiac blood-flow quantification |
| HICON® Sodium Iodide I-131 Solution USP | I-131, therapeutic | Hyperthyroidism and selected carcinoma of the thyroid | No direct competition in the US market. Also used diagnostically |
| MIBG (Metaiodobenzylguanidine) | I-131, therapeutic | Relapsed/refractory paediatric neuroblastoma | Pipeline. Phase 2 dosing complete; data package to FDA Apr–Jun 2026; pre-NDA meeting targeted by Sep 2026; NDA filing H2 FY2027; launch targeted CY2027. Potential peak sales US$70–100 million |
| New PET and SPECT pipeline | Various | Various | 9 launches planned FY2027–FY2029 across a US$550 million incremental TAM with US$120 million potential peak annual sales (FY2027: 1 launch, US$30m TAM; FY2028: 4 launches, US$250m; FY2029: 4 launches, US$270m) |
Pricing model: not disclosed at product level. Radiopharmaceuticals are sold on contract and per-dose bases into hospital and GPO channels.
Radiopharmacy (Jubilant Radiopharmacies division)
45 radiopharmacies: in the US (42 SPECT, 3 PET as at Q3 FY2026; the FY2024 annual report cited 46 sites comprising 43 SPECT and 3 PET), serving approximately 1,800 hospitals, with roughly 20% volume market share and six customised doses delivered every minute
-
99%+ on-time delivery, using AI for route optimisation, with an owned delivery fleet
-
Full USP<825> compliance across the network
-
Distributes third-party products including PYLARIFY, Illuccix, Neuraceq, FDG, and — newly in FY2026 — Pluvicto (Lu-177 vipivotide tetraxetan) and Lutathera, the leading radioligand therapies for prostate and neuroendocrine cancer
-
Access strategy targets the three largest US group purchasing organisations (Premier, HealthTrust, Vizient). In FY2024, Ga-68 PSMA agent availability was extended to ten additional markets, taking total coverage to 38 markets
Expansion programme: US$50 million (subsequently described as US$60m+) to take the PET network from 3 sites to 9 sites, fully operational by FY2028, targeting 1.0x asset turnover and 20%+ RoCE
Allergy Immunotherapy (Jubilant HollisterStier, Spokane, Washington)
| Product family | Description | Positioning |
|---|---|---|
| Venom extracts | Honey bee and other stinging-insect venom extracts (6 venom extracts) | Sole supplier in the United States |
| Allergenic extracts | 200+ allergenic extracts — dog, cat, mite, tree, pollen, mould and others | 2nd largest player in the US subcutaneous immunotherapy market |
| Skin testing devices | Multiple specialised skin-testing systems | Diagnostic complement to the therapeutic range |
Brand heritage: the "HollisterStier" name is over 100 years old. Manufacturing is onshore, USFDA-approved, supported by a dedicated US sales force covering approximately 2,000 allergist and ENT customers. International markets served include Canada, Europe and Australia. Growth strategy is threefold: retain and grow US venom customers; increase allergenic-extract revenue through targeted marketing; and expand outside-US venom sales via European partnerships, alongside increased R&D in new products and technologies.
CDMO Sterile Injectables (Jubilant HollisterStier — Spokane, Washington and Kirkland/Montreal, Canada)
Service catalogue:
Sterile fill and finish: liquid and lyophilised (freeze-dried) injectables
Ophthalmic full-service offer: liquids, ointments and creams, including multi-dose preservative-free ophthalmic drops
Ampoules: - Biologics fill-finish
Non-sterile products: (Montreal)
Capacity and capability:
Spokane Line 1 and Line 2: established commercial lines; 10+ years of continuous USFDA-compliant status
Spokane Line 3: US$132 million investment, launched October 2025, isolator technology, adds 50% capacity. 10+ products in technology transfer as at Q1 FY2027, including one of the world's largest oncology products. Commercial batch production expected late FY2027 subject to USFDA approval; full utilisation in approximately 3.5 years; peak revenue potential US$80–90 million
Spokane Line 4: installation completed as at Q1 FY2027; technology-transfer revenue expected from Q4 FY2027; commercial production FY2028; peak revenue potential US$80–90 million
Montreal Line 5 (new isolator fill & finish line): construction started, plant and machinery ordered; capex US$114 million with a US$35 million concessional loan (the Government of Quebec, via Investissement Québec, previously granted a CAD 25 million loan including a CAD 6.3 million forgivable portion toward a CAD 100 million Montreal expansion). Technology-transfer revenue expected FY2029
Customer base: 5 of the top 20 global pharmaceutical companies; 25+ customers worldwide; 5+ years average relationship with top 10 customers; 90%+ repeat business; 92% customer retention. Regulatory approvals span USFDA, EMA, PMDA Japan, Health Canada, ANVISA Brazil and other authorities.
Pricing model: long-duration commercial contracts, typically three years or more with auto-renewal, plus fee-based technology transfer programmes.
CRDMO — Drug Discovery Services (Jubilant Biosys Limited)
| Facility | Location | Scientists | Capability |
|---|---|---|---|
| Integrated Drug Discovery Centre (IDDC) | Bengaluru, Karnataka | ~350 | Target identification through candidate selection; immuno-oncology expertise |
| Chemistry Research Innovation Centre (CIRC) | Greater Noida, Uttar Pradesh | ~750 | Synthetic, medicinal, analytical and computational chemistry |
| Investigational New Drug Centre (INDC) | Noida, Uttar Pradesh | — | Preclinical CRDMO services; new discovery and preclinical facility opened January 2026 with R&D labs and two pilot plants, doubling chemistry scale-up capacity |
| Centre of Excellence — Biologics | St Julien, France | ~35 | Antibody-drug conjugates, monoclonal antibodies, biologics — added via the Pierre Fabre partnership |
Service lines: structural biology; computational chemistry; medicinal and synthetic chemistry; in-vitro and in-vivo biology; DMPK; toxicology; process R&D and manufacturing; ADC and mAb discovery spanning antibody engineering, linker-payload design and conjugation; complex molecule synthesis including PROTAC, PHOTAC and LYTAC.
Track record: 85+ integrated discovery programmes delivered; approximately 40 clients in the last three years; 8 of the top 20 pharmaceutical companies as customers with a 5x increase in revenue share from large pharma; 1,200+ scientists across five sites in India and Europe.
Capacity roadmap: 1,000 FTEs (FY2025) → 2,000 FTEs (FY2028) → 4,000 FTEs (FY2030), via expansion at Greater Noida and Bengaluru plus a new site at Devanahalli, Bengaluru. Total capex US$150 million with an expected RoCE above 20%.
Pricing model: fee-for-service (FFS) contracts and FTE-based engagements; management has cited growing demand specifically for FFS.
CRDMO — CDMO API (Nanjangud, Karnataka)
-
Site area approximately 267,700 square metres; six multi-stream manufacturing blocks (multi-tonne volume) plus a pilot plant (up to 20 kg); volumetric capacity approximately 785 kL; ~190 reactors ranging 0.1 kL to 15 kL; 20+ clean rooms; 900+ MT of annual capacity; over 900 personnel
-
Potent API capability across OEB Class 1–4
-
Complex chemistry expertise: chiral separation, low-temperature reactions, biotransformation, stereo-selective synthesis
-
Approvals: USFDA, PMDA Japan, KFDA Korea, ANVISA Brazil; classified VAI by USFDA following an FY2023 inspection
-
Dedicated on-site R&D centre and DoE/QbD cell; GMP kilo lab commissioned to bridge gram-to-kilogram scale-up
-
Regulatory filings (as at March 2022, the most recent comprehensive disclosure located): 98 US DMFs, 46 European CEPs, 40 Canadian DMFs, 15 Japanese DMFs, 14 Australian DMFs
Generics (Jubilant Generics Limited; Roorkee, Uttarakhand, plus CMO network; Salisbury, Maryland)
Dosage forms: immediate-release coated and uncoated tablets, bi-layered tablets, hard gelatin capsules, powder for oral suspension; NDDS-based extended/delayed/sustained release, orally disintegrating and chewable/dispersible tablets; MUPS; ophthalmics; injectables; veterinary formulations
Therapeutic areas: cardiovascular, central nervous system, gastrointestinal, multi-specialty
Geographic reach: 50+ markets including the US, Europe, Canada, Japan and Australia
R&D: Noida-based dosage development, API and BA/BE centres with 400+ scientists, supporting registrations in the US, EU, Canada, Japan, China, Australia, South Africa, Brazil and rest-of-world
Recent approvals: Dextroamphetamine Saccharate (USFDA approval, April 2026); Pantoprazole Sodium Delayed Release Oral Suspension 40 mg per packet (tentative approval 25 June 2026, final approval expected on reference-drug patent expiry in December 2026; addressable US market estimated at US$40–45 million)
Historic product of note: JUBI-R, an in-house Remdesivir lyophilised injection launched under India's emergency authorisation during the COVID-19 pandemic, with in-house API
Strategy: 6–8 new product launches annually; relaunch dormant ANDAs from Roorkee and the CMO network; in-license and acquire targeted ANDAs; build a branded India presence in diabetes, dyslipidaemia, hypertension and weight management; scale 3–4 key non-US markets on a B2B2C model
Proprietary Novel Drugs (Jubilant Therapeutics Inc., Yardley, Pennsylvania)
| Programme | Mechanism | Indications | Stage | US TAM |
|---|---|---|---|---|
| JBI-802 | First-in-class oral dual inhibitor of LSD1 and HDAC6 within the CoREST complex | Essential Thrombocythemia / MPN resistant to cytoreductive therapy (company-sponsored Phase II) | Phase II underway; interim data expected 2026 | US$3.3bn |
| — | — | mSTK11 IO-resistant NSCLC (investigator-led Phase II) | Ongoing; early data 2026 | US$3.1bn |
| — | — | Post-MPN AML (investigator-led Phase II) | Planned; first patient in 1H 2026 | US$0.8bn |
| JBI-778 | Substrate-competitive, brain-penetrant PRMT5 inhibitor addressing both MTAP-null and wild-type tumours | NSCLC with EGFR mutation | Phase I underway (first-in-human, India) | US$2.0bn |
| — | — | High-grade glioma | Phase I | US$1.7bn |
| — | — | Adenoid cystic carcinoma (head and neck) | Phase I | — |
| PDL1 inhibitors | Brain-penetrant and gut-restrictive | Oncology, inflammatory | Preclinical | — |
| PAD4 inhibitor | PAD4 inhibition | Autoimmune disease | IND track | — |
Discovery platform: TIBEO (Therapeutic Index and Brain Exposure Optimization) — a structure-based drug design engine combining computational modelling, unique proprietary scaffolds, selectivity screening, mutation-driven cell screening, ADME with brain focus, toxicology, site-specific targeting and genetically-defined patient selection.
Both lead assets hold FDA Orphan Drug designations. Reported clinical signals for JBI-802 include a stage-IV NSCLC patient with confirmed partial response and approximately 40% tumour reduction sustained beyond two years, and a patient with over 50% shrinkage of liver metastasis with complete resolution of related portal hypertension. Scientific guidance is provided by oncologists from Memorial Sloan Kettering and Dana-Farber.
Financial Narrative
All figures consolidated, in ₹ crore unless stated, for fiscal years ended 31 March. FY2022 is the first fully comparable post-demerger year.
Company-reported EBITDA and normalised earnings: notes and sources
The company began consistently presenting a "normalised PAT" (adjusted for exceptional items and related tax) in FY2025 disclosures. FY2023 and FY2024 normalised PAT were not disclosed on a comparable basis and are shown as zero placeholders rather than estimated. FY2025 normalised PAT of ₹413 crore is derived from the disclosed 7% FY2026 growth to ₹442 crore.
Margin progression (%)
Gross profit is not separately disclosed in the company's Ind AS statutory presentation, which reports cost of materials consumed, purchases of stock-in-trade and changes in inventories as distinct lines rather than a consolidated cost of goods sold. Third-party gross-margin estimates for this company vary between 20% and 70% depending on treatment of the radiopharmacy pass-through, and are therefore not reliable and are excluded.
Net debt and leverage (company-reported, constant currency, net of deferred income on capital): notes and sources
FY2026 year-end net debt was not separately disclosed in the Q4 FY2026 release reviewed. FY2023 net debt to EBITDA was 2.93x. The FY2024 long-term capex creditors figure was not disclosed and is shown as zero placeholder. Note that reported total borrowings rose ₹884 crore in FY2026 while capex creditors also rose sharply — the balance sheet is being levered to fund the Spokane and PET build-outs.
Goodwill and intangibles are not separately disclosed in the summary balance sheet data reviewed; they are embedded within the fixed assets line. This is a genuine information gap for a company that grew historically by acquisition (Draxis, HollisterStier, Cadista).
Working capital improved materially: the cash conversion cycle compressed from 224 days in FY2022 to 47 days in FY2026, and working capital days from 56 to 13.
Ratio analysis: notes and sources
Current ratio and quick ratio are not reported here because the sources reviewed conflict materially (one aggregator reports 2.05x current ratio, another implies 1.66x on short-term assets of ₹34.6bn versus short-term liabilities of ₹20.9bn). Return on invested capital is likewise not calculated because invested-capital composition requires balance-sheet detail not available in the summary data reviewed; the company's own ROCE definition — EBIT before exceptional items divided by average of (equity plus gross debt) less (CWIP adjusted for grant) — is disclosed and its output is shown in the ROCE row above as "high single digit" for 9M FY2026 annualised, versus a Vision 2030 target of "high teens."
Commentary on trends, inflections and drivers
FY2022 — the clean baseline that immediately deteriorated. Revenue of ₹6,130 crore at an 18.8% operating margin represented the post-demerger starting point, still carrying residual COVID-era tailwinds (Remdesivir, COVID-related CDMO work). Net profit of ₹413 crore. Interest coverage of 7.9x. This was the high-water mark for margin and coverage.
FY2023 — the trough. Operating margin collapsed 640 basis points to 12.4%, the company posted a net loss of ₹65 crore, and depreciation spiked to ₹554 crore (an accelerated charge, likely impairment-related given the ₹57 crore exceptional cost flagged in Q2 FY2023). Four things went wrong simultaneously: COVID-era CDMO and generics revenue disappeared against a high base; the Roorkee import alert kept the generics business loss-making at a −18% EBITDA margin; the Montreal facility received an OAI classification; and finance costs rose 30% as leverage peaked at 0.68x debt/equity and 2.93x net debt/EBITDA. The 333% effective tax rate reflects tax charges on a near-zero pre-tax base — an arithmetic artefact, not a cash event.
FY2024 — stabilisation without recovery. Revenue grew 6.7% and reported EBITDA 20% to ₹994 crore, but net profit of only ₹73 crore against a dividend payout of ₹80 crore — a 102% payout ratio funded from reserves. Other income was negative ₹76 crore, reflecting forex and associate-level charges. Q4 FY2024 was a loss quarter (−₹62 crore net). Free cash flow of ₹83 crore against ₹888 crore of capex signalled the beginning of the heavy investment cycle.
FY2025 — the flattering year. Reported net profit of ₹836 crore (+988%) and 14.3% ROE look transformational but are almost entirely non-operating. Other income swung to +₹416 crore, driven by the Sofie Biosciences disposal gain (net exceptional income of ₹382 crore in 9M FY2025), and the effective tax rate fell to 15%. Strip these out: normalised PAT was ₹413 crore. The genuine operating achievement was real but narrower — EBITDA margin expanded 230 basis points to 17.0%, net debt halved to ₹1,348 crore using US$75 million of Sofie proceeds, and the cash conversion cycle compressed from 124 to 65 days.
FY2026 — growth purchased at the cost of margin. Revenue accelerated to +14.5%, the fastest in the post-demerger period, and EBITDA reached a record ₹1,326 crore. But EBITDA margin contracted 99 basis points to 15.9%, depreciation jumped 19% to ₹440 crore as Line 3 and other assets were capitalised, and reported net profit fell 52% to ₹398 crore against the inflated FY2025 base. Normalised PAT grew just 7% to ₹442 crore. Free cash flow was negative ₹120 crore — the second consecutive negative year — and total borrowings rose ₹884 crore. The proximate cause of the margin miss is specific and identifiable: the Montreal shutdown, which removed high-margin SPECT product supply and imposed remediation costs and under-absorption.
The inflection to watch. The company has now invested through a full cycle: CWIP has risen from ₹1,090 crore (FY2022) to ₹4,040 crore (FY2026), a 3.7x increase, while revenue rose only 35%. Roughly ₹4,000 crore of capital is sitting on the balance sheet not yet generating return. That is simultaneously the bull case (embedded operating leverage) and the bear case (a very large sum earning nothing while depreciation and interest accrue).
Q1 FY2027 — the warning shot. Revenue +17% to ₹2,229 crore, but EBITDA fell 11% to ₹268 crore, margin down 385 basis points to 11.9%, and PAT down 45% to ₹56 crore. Growth without margin is now a two-quarter pattern, not a one-quarter aberration.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Revenue
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Radiopharmaceuticals | 952 | 1,074 | 1,178 |
Radiopharmacy | 2,050 | 2,314 | 2,512 |
Radiopharma (total) | 3,002 | 3,388 | 3,690 |
Allergy Immunotherapy | 679 | 701 | 785 |
CDMO Sterile Injectables | 1,117 | 1,272 | 1,755 |
CRDMO Drug Discovery Services | 449 | 570 | 654 |
CRDMO CDMO-API | 645 | 581 | 563 |
CRDMO (total) | 1,094 | 1,151 | 1,217 |
Generics | 775 | 685 | 774 |
Proprietary Novel Drugs | 0 | 0 | 0 |
Unallocable corporate income | 36 | 38 | 59 |
Total revenue from operations | 6,703 | 7,234 | 8,280 |
Segment Revenue (FY2025–FY2026)
| Segment | FY2025 | FY2026 |
|---|---|---|
Radiopharmaceuticals | 12.8 | 9.7 |
Radiopharmacy | 12.9 | 8.6 |
Allergy Immunotherapy | 3.2 | 12.0 |
CDMO Sterile Injectables | 13.9 | 38.0 |
CRDMO Drug Discovery Services | 27.0 | 14.7 |
CRDMO CDMO-API | -9.9 | -3.1 |
Generics | -11.6 | 13.0 |
Total revenue from operations | 7.9 | 14.5 |
Segment Margins & Growth (%)
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Radiopharmaceuticals | 50 | 47 | 41 |
Radiopharmacy | 3 | 1 | 1 |
Allergy Immunotherapy | 40 | 35 | 35 |
CDMO Sterile Injectables | 17 | 23 | 18 |
CRDMO Drug Discovery Services | 24 | 24 | 23 |
CRDMO CDMO-API | 10 | 15 | 14 |
Generics | -18 | 3 | 11 |
Group EBITDA margin (reported) | 15 | 17 | 16 |
Segment Revenue — Radiopharmaceuticals
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Radiopharmaceuticals | 476 | 505 | 478 |
Radiopharmacy | 62 | 23 | 36 |
Allergy Immunotherapy | 272 | 245 | 278 |
CDMO Sterile Injectables | 190 | 293 | 314 |
CRDMO Drug Discovery Services | 108 | 137 | 150 |
CRDMO CDMO-API | 65 | 87 | 81 |
Generics | -140 | 21 | 83 |
Proprietary Novel Drugs | -20 | -19 | -16 |
Unallocable corporate | -60 | -62 | -78 |
Group EBITDA (reported) | 994 | 1,230 | 1,326 |
Segment Revenue — Radiopharma
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Radiopharma | 44.8 | 46.8 | 44.6 |
Allergy Immunotherapy | 10.1 | 9.7 | 9.5 |
CDMO Sterile Injectables | 16.7 | 17.6 | 21.2 |
CRDMO | 16.3 | 15.9 | 14.7 |
Generics | 11.6 | 9.5 | 9.3 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 6,130 | 6,282 | 6,703 | 7,234 | 8,280 |
Total operating expenses (INR Cr) | 4,980 | 5,503 | 5,802 | 6,061 | 7,020 |
Operating profit before other income (INR Cr) | 1,150 | 779 | 901 | 1,173 | 1,260 |
Other income (INR Cr) | 8 | -9 | -76 | 416 | 7 |
Depreciation and amortisation (INR Cr) | 382 | 554 | 382 | 369 | 440 |
Finance costs (INR Cr) | 145 | 188 | 272 | 240 | 212 |
Profit before tax (INR Cr) | 630 | 28 | 170 | 981 | 614 |
Effective tax rate (%) | 34 | 333 | 57 | 15 | 35 |
Reported net profit (INR Cr) | 413 | -65 | 73 | 836 | 398 |
Basic earnings per share (INR) | 25.98 | -3.83 | 4.84 | 52.69 | 25.02 |
Diluted earnings per share (INR) | 25.98 | -3.83 | 4.84 | 52.69 | 25.02 |
Dividend per share (INR) | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
Dividend payout ratio (%) | 19 | -130 | 102 | 9 | 20 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (FY2023–FY2026)
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
EBITDA as reported by company (INR Cr) | 828 | 994 | 1,230 | 1,326 |
EBITDA margin as reported (%) | 13.2 | 14.7 | 17.0 | 15.9 |
Normalised profit after tax (INR Cr) | 0 | 0 | 413 | 442 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating margin before other income (%) | 18.8 | 12.4 | 13.4 | 16.2 | 15.2 |
Profit before tax margin (%) | 10.3 | 0.4 | 2.5 | 13.6 | 7.4 |
Net profit margin (%) | 6.7 | -1.0 | 1.1 | 11.6 | 4.8 |
Valuation Snapshot
| Metric | Value |
|---|---|
Revenue CAGR FY2022–FY2026 (%) | 7.8 |
Revenue CAGR FY2021–FY2026, five-year (%) | 6.3 |
Revenue CAGR FY2023–FY2026, three-year (%) | 9.6 |
Revenue growth FY2026 (%) | 14.5 |
Trailing twelve-month revenue growth to Q1 FY2027 (%) | 16.0 |
Share price, close 17 August 2026 (INR) | 867 |
Market capitalisation (INR Cr) | 13,832 |
Shares outstanding | 159,281,140 |
Face value per share (INR) | 1 |
52-week high (INR) | 1,185 |
52-week low (INR) | 784 |
Book value per share (INR) | 445 |
Beta | 1.34 |
Price to earnings, trailing (x) | 35.6 |
Price to book (x) | 1.95 |
Enterprise value to EBITDA, approximate (x) | 12.1 |
Enterprise value to sales, approximate (x) | 1.9 |
Dividend yield (%) | 0.58 |
Earnings yield (%) | 2.8 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 9,830 | 10,929 | 11,338 | 12,584 | 15,272 |
Equity share capital (INR Cr) | 16 | 16 | 16 | 16 | 16 |
Reserves and surplus (INR Cr) | 5,303 | 5,383 | 5,418 | 6,239 | 7,077 |
Total shareholders equity (INR Cr) | 5,319 | 5,399 | 5,434 | 6,255 | 7,093 |
Total borrowings (INR Cr) | 3,192 | 3,677 | 3,664 | 2,731 | 3,615 |
Other liabilities (INR Cr) | 1,319 | 1,853 | 2,240 | 3,598 | 4,564 |
Net fixed assets (INR Cr) | 4,871 | 5,183 | 5,091 | 5,176 | 6,966 |
Capital work in progress (INR Cr) | 1,090 | 1,562 | 2,103 | 3,630 | 4,040 |
Non-current investments (INR Cr) | 239 | 256 | 42 | 44 | 61 |
Other assets including current assets (INR Cr) | 3,631 | 3,928 | 4,101 | 3,735 | 4,205 |
Cash Flow and Financial Ratios (x)
| Metric | FY2024 | FY2025 | Q3 FY2026 |
|---|---|---|---|
Net debt (INR Cr) | 2,457 | 1,348 | 1,751 |
Net debt to equity (x) | 0.45 | 0.22 | 0.28 |
Net debt to trailing EBITDA (x) | 2.48 | 1.10 | 1.30 |
Interest coverage, EBITDA to interest (x) | 3.70 | 5.10 | 6.30 |
Long-term capex creditors (INR Cr) | 0 | 453 | 701 |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash from operating activities (INR Cr) | 838 | 661 | 971 | 1,072 | 1,227 |
Capital expenditure (INR Cr) | 597 | 796 | 888 | 1,110 | 1,347 |
Free cash flow (INR Cr) | 241 | -135 | 83 | -38 | -120 |
Cash from investing activities (INR Cr) | -323 | -474 | -596 | 512 | -1,143 |
Cash from financing activities (INR Cr) | -33 | -157 | -432 | -1,453 | 95 |
Net change in cash (INR Cr) | 482 | 30 | -58 | 132 | 179 |
Dividends paid (INR Cr) | 80 | 80 | 80 | 80 | 80 |
Share buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Operating cash flow to operating profit (%) | 90 | 111 | 131 | 112 | 114 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Return on equity on average equity (%) | 8.2 | -1.2 | 1.3 | 14.3 | 6.0 |
Return on assets on average assets (%) | 4.4 | -0.6 | 0.7 | 7.0 | 2.9 |
Return on capital employed (%) | 10 | 3 | 7 | 10 | 9 |
Total debt to equity (x) | 0.60 | 0.68 | 0.67 | 0.44 | 0.51 |
Interest coverage, EBITDA to interest (x) | 7.9 | 4.1 | 3.7 | 5.1 | 6.3 |
Asset turnover on average assets (x) | 0.66 | 0.61 | 0.60 | 0.60 | 0.59 |
Debtor days | 55 | 56 | 50 | 45 | 47 |
Inventory days | 308 | 268 | 220 | 178 | 170 |
Days payable | 139 | 160 | 146 | 158 | 170 |
Cash conversion cycle days | 224 | 165 | 124 | 65 | 47 |
Working capital days | 56 | 57 | 56 | 16 | 13 |
Revenue by Region (%)
| Metric | 9M FY2026 |
|---|---|
Share of revenue from United States (%) | 81 |
Share of revenue from rest of world (%) | 19 |
Share of revenue denominated in US dollars (%) | 94 |
Share of revenue in other currencies (%) | 6 |
Origin Details
| Origin | Share of US-destined revenue (%) |
|---|---|
United States | 74 |
Canada | 17 |
India | 9 |
Revenue by Region and Revenue by Region (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
North America centric segment revenue (INR Cr) | 4,798 | 5,361 | 6,230 |
North America centric share of total revenue (%) | 71.6 | 74.1 | 75.2 |
India and rest of world centric segment revenue (INR Cr) | 1,869 | 1,836 | 1,991 |
India and rest of world centric share of total revenue (%) | 27.9 | 25.4 | 24.0 |
North America centric segment growth (%) | 0.0 | 11.7 | 16.2 |
India and rest of world centric segment growth (%) | 0.0 | -1.8 | 8.4 |
Capital Markets
| Metric | Value (%) |
|---|---|
Share price CAGR, 10 years | 7 |
Share price CAGR, 5 years | 7 |
Share price CAGR, 3 years | 26 |
Share price return, 1 year | -18 |
Per-Share Data and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share (INR) | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
Dividend as percentage of face value (%) | 500 | 500 | 500 | 500 | 500 |
Dividend payout ratio (%) | 19 | -130 | 102 | 9 | 20 |
Total dividend outflow (INR Cr) | 80 | 80 | 80 | 80 | 80 |
Credit Ratings
| Agency | Instrument | Rating | Outlook | Date |
|---|---|---|---|---|
India Ratings & Research (Fitch Group) | Long-term issuer rating | IND AA+ | Stable | Affirmed 5 May 2025; outlook revised to Stable 9 December 2024 |
India Ratings & Research | Bank facilities | IND AA+ / IND A1+ | Stable | 5 May 2025 |
India Ratings & Research | Commercial paper programme | IND A1+ | — | Assigned 5 May 2025 |
India Ratings & Research | Rating update issued | Details not accessible | — | 24 February 2026 |
CRISIL Ratings | Long-term bank facilities and NCDs | Withdrawn at company request | — | 6 May 2021, following transfer of ₹460 crore of facilities to Jubilant Ingrevia |
Analyst Conclusions
Management guidance
Management has issued no numeric guidance for FY2027. The qualitative commitments are precise enough to be testable:
-
Growth momentum will strengthen in FY2027 relative to FY2026's 14.5%
-
EBITDA margins will strengthen from H2 FY2027 as Montreal production stabilises
-
Montreal operating losses will taper off in H2 FY2027; Montreal segment EBITDA breakeven targeted in FY2028
-
Full SPECT product availability by H2 FY2027, with batch releases from Q2 FY2027
-
Margin recovery will "effectively offset higher depreciation costs and drive net profit growth"
-
Net debt to EBITDA to remain range-bound
-
Line 3 commercial batch production from late FY2027 subject to FDA approval; Line 4 technology transfer revenue from Q4 FY2027
-
Vision 2030: ₹13,500 crore revenue, 23–25% EBITDA margin, zero net debt, high-teens RoCE
Consensus growth expectations
The implied arithmetic of the Vision 2030 target requires a 13.0% revenue CAGR from FY2026 to FY2030 and 700–900 basis points of EBITDA margin expansion. Revenue is currently running ahead of that requirement (16% TTM). Margin is running 400 basis points behind the FY2024 starting point.
Three bull-case arguments
Bull 1 — The margin problem is dated, localised and already reversing. Every basis point of the FY2026 and Q1 FY2027 margin decline traces to one facility. Montreal has now completed media fills, resumed commercial batch production of SPECT products, and has batch releases scheduled for Q2 FY2027 with full availability in H2. Radiopharmaceuticals is a 40–47% margin business; restoring roughly ₹300 crore of annualised high-margin SPECT revenue mechanically restores 150–200 basis points of group margin. Meanwhile Spokane — the part of CDMO that is working — grew 43% with EBITDA up 49% at a 24% margin in Q1 FY2027. The underlying franchise did not deteriorate; one plant did.
Bull 2 — ₹4,040 crore of capital work in progress is a coiled spring. CWIP has risen 3.7x since FY2022 against 35% revenue growth. That capital is not lost — it is Lines 3, 4 and 5, six PET radiopharmacies and the CRDMO expansion, all with disclosed return targets above 20% RoCE and disclosed peak revenue potentials (US$160–180 million from Lines 3 and 4 alone, against total FY2026 CDMO revenue of ₹1,755 crore, or roughly US$195 million). As these assets commission, incremental revenue arrives at high incremental margin against already-charged depreciation. Group ROCE of 9% against a high-teens target is a measure of how much return is currently being withheld, not destroyed.
Bull 3 — Structural tailwinds are unusually well-aligned and rarely coincide. The US radiopharmaceutical market compounds at 20% toward US$20 billion by 2030, validated by US$9 billion of large-cap M&A in three years. The US sterile injectable market faces a 700-million-vial shortfall by 2027, made worse by Catalent's absorption into Novo Holdings. US tariff policy is actively pushing innovators to onshore, and Jubilant already has the isolator capacity in Washington State. The Biosecure Act redirects discovery demand to India, where Jubilant has 1,200 scientists and 8 of the top 20 pharma companies as clients. Each of these is independently powerful; together they are a rare configuration.
Three bear-case arguments
Bear 1 — The FDA pattern is the business risk, not an accident. Eight years, four sites, and a repeating cycle: Roorkee OAI (2018) → Warning Letter (2019) → import alert (2021) → six observations and OAI (2022) → VAI (2024); Montreal OAI (2023) → OAI again (2026) → Warning Letter (2026); Spokane eight observations (2026). Any individual event is defensible. The sequence suggests quality systems that repeatedly fall behind an escalating regulatory standard. The consequence is not merely lost quarters: under OAI the FDA may withhold approval of pending applications listing the facility — which is exactly the mechanism that could delay the nine-product FY2027–FY2029 pipeline on which one-third of the Vision 2030 revenue bridge depends.
Bear 2 — Free cash flow has been negative for two years and the balance sheet is absorbing it. FCF was −₹38 crore (FY2025) and −₹120 crore (FY2026). Borrowings rose ₹884 crore in FY2026. Long-term capex creditors rose from ₹453 crore to ₹701 crore in nine months. Net debt rose from ₹1,348 crore (March 2025) to ₹1,751 crore (December 2025) despite the FY2025 Sofie windfall of US$117 million. Depreciation rose 19% while EBITDA rose 8%. The company is paying an ₹80 crore dividend every year — including in a loss year — while running negative FCF and a Vision 2030 target of zero net debt. Those two commitments cannot both be met without a sharp and sustained inflection in operating cash generation.
Bear 3 — The largest business is economically inert and the fix is unproven. Radiopharmacy is 30% of group revenue at a 1.4% EBITDA margin. Vision 2030 requires it to reach 7–8% on a doubled revenue base — an outcome that depends entirely on six new PET sites, competing directly against a network with 160+ locations and 4,100 hospitals, in a segment where the company itself concedes "competitive intensity in SPECT radiopharmacy continues." If PET expansion delivers volume without margin — precisely the outcome of the last three years in that division — the group margin target is arithmetically unreachable and the multiple compresses toward the earnings.
Catalysts and monitorables for the next twelve months
| Timing | Catalyst | Why it matters |
|---|---|---|
| Q2 FY2027 (Sep–Oct 2026) | SPECT batch releases from Montreal | The first hard evidence the recovery is real, not scheduled |
| H2 FY2027 | Full SPECT product availability and the promised margin inflection | The single most important number in the story |
| Ongoing | Resolution of the Montreal Warning Letter | Until closed, pending applications listing the facility remain at risk |
| Within 15 business days of 17 Jun 2026, then follow-up | Spokane response to 8 observations and the resulting classification | Spokane is now the growth engine; an OAI here would be far more damaging than Montreal |
| Late FY2027 | Line 3 commercial batch production, subject to FDA approval | Converts technology-transfer revenue into higher-margin commercial revenue |
| Q4 FY2027 | Line 4 technology transfer revenue commencement | Confirms the capacity pipeline is on schedule |
| Dec 2026 | Pantoprazole final approval on RLD patent expiry | Roughly US$40–45 million addressable; validates the Roorkee restart |
| Sep 2026 | MIBG pre-NDA meeting with FDA | Gates an NDA filing in H2 FY2027 for a US$70–100 million peak-sales asset |
| CY2026 | JBI-802 and JBI-778 clinical data readouts | The trigger for the stated monetisation exploration |
| FY2028 (progress reported quarterly) | PET radiopharmacy site commissioning, 3 to 9 | The single largest lever in the Vision 2030 margin bridge |
| Each quarter | Free cash flow, net debt and capex creditors | Determines whether the zero-net-debt target survives contact with the capex programme |
| Each quarter | Ruby-Fill install base growth | Ran 21%, then 35%, then 26% YoY; deceleration would signal Lantheus competitive pressure |
| Aug 2027 (Aug 2026 baseline) | US generic import tariff, effective after a two-year grace period | Directly affects the Roorkee-based US generics plan |
| Ongoing | New permanent CFO's first full reporting cycle | Third CFO in three years; execution credibility matters |
Concluding analyst verdict
Jubilant Pharmova is a company whose assets are considerably better than its arithmetic, and the gap between the two is the entire investment case.
The asset base is genuinely hard to replicate. A radiopharmaceutical franchise with a US monopoly product, the number-two US radiopharmacy network, a sole-supplier position in venom immunotherapy, and onshore US sterile fill-finish capacity at precisely the moment tariff policy rewards it — that combination does not exist elsewhere in the Indian listed universe and barely exists globally. The moats are structural rather than contractual: nuclear licences, 4,000-hour pharmacist certifications, 18-to-24-month technology transfers, isotope half-lives measured in hours. These are not eroded by a bad quarter.
The arithmetic is where the problem sits. Revenue growth accelerated to 14.5% in FY2026 and 17% in Q1 FY2027 — the best in the post-demerger era. Yet EBITDA margin fell 99 basis points in FY2026 and a further 385 basis points in Q1 FY2027, free cash flow was negative for a second consecutive year, borrowings rose ₹884 crore, and RoCE of 9% remains below the FY2022 level. The company has invested ₹4.4 crore of capital work in progress for every ₹1 crore of incremental FY2026 revenue. Management's explanation — Montreal — is honest, specific and largely correct. But it is also the third distinct FDA-driven earnings disruption in eight years, at the third distinct facility, and that changes it from bad luck into a risk factor requiring a probability weighting rather than an apology.
The resolution is not far away and is unusually testable. By H2 FY2027 investors will know whether SPECT supply has fully normalised, whether the margin inflection management has promised actually arrives, whether Spokane's eight observations resolve benignly, and whether the first PET radiopharmacies commission on schedule. Those four outcomes will determine whether Vision 2030's 23–25% EBITDA margin is a plan or an aspiration.
At 35.6x trailing earnings and roughly 12x EV/EBITDA, with the stock 30% below its all-time high and foreign institutions having exited 733 basis points of the register over three years, the market is pricing meaningful scepticism about execution while still paying a specialty-pharma multiple for the franchise. That is, on balance, a fair place for it to sit. The appropriate posture is constructive but conditional: the franchise merits a premium, the capital cycle merits patience, and the compliance record merits a discount. Investors should size positions to the recognition that the single most important variable — an FDA classification at a Canadian plant — is not within management's control, and that the company has not yet demonstrated it can hold three regulated sites clean simultaneously through a period of heavy expansion.
APPENDIX A — DATA SOURCES AND CONFIDENCE NOTES
Primary sources relied upon: Jubilant Pharmova quarterly results releases and earnings presentations (Q3 FY2026 earnings presentation used extensively for segment, market-sizing and Vision 2030 data); Q4/FY2026 results release (22 May 2026); Q1 FY2027 results release (10 August 2026); Q2 FY2026 press release (31 October 2025); Annual Report 2023-24; company websites (jubilantpharmova.com, jubilantpharma.com, jubilantbiosys.com, jubilanttx.com); BSE and NSE regulatory filings as summarised by financial data providers; India Ratings & Research and CRISIL Ratings public rating actions; postal ballot notice (July 2026).
Secondary sources: screener.in (consolidated financial statement series FY2015–FY2026, sourced from company filings via C-MOTS Internet Technologies); trendlyne (shareholding pattern detail); Business Standard, ANI, Indian Pharma Post, Medical Dialogues, EquityBulls, Business Upturn, ScanX and other Indian financial media for event-level newsflow; Sustainalytics; Tracxn (MCA registry data).
End of dossier.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | On board since | Notes |
|---|---|---|---|
Shyam S. Bhartia | Chairman | Founder | Co-founder of the Jubilant Bhartia Group; 44+ years of experience across pharma, specialty chemicals, foods, oil and gas, aerospace and IT; age approximately 74 |
Hari S. Bhartia | Co-Chairman, Non-Executive Director | Founder | Co-founder; 38+ years of experience across the same sectors; served as Managing Director until 31 May 2023; Chairman of Jubilant Therapeutics Inc.; age approximately 70 |
Priyavrat Bhartia | Managing Director | May 2017 (as NED); MD from 1 Jun 2023 | Son of Shyam S. Bhartia. Age 49. BA Economics, Dartmouth College; MBA, Stanford University. c.29 years of industry experience. Also on the boards of Jubilant Ingrevia, Jubilant Industries, HT Media, Digicontent and Hindustan Media Ventures. Reappointed for three years from 1 June 2026 |
Arjun Shanker Bhartia | Joint Managing Director | May 2017 (as NED); Joint MD from 1 Jun 2023 | Son of Hari S. Bhartia. Age 39. Graduate of Brown University (2008). Associate Consultant at Bain & Company 2008–2010. Also on the boards of Jubilant Consumer and Jubilant Enpro. Reappointed for three years from 1 June 2026 |
Arvind Chokhany | Group Chief Financial Officer and Whole-Time Director | Whole-time Director; DIN 06668147 | Group CFO of the Jubilant Bhartia Group; served as Jubilant Pharmova CFO from 1 June 2023 until the interim CFO appointment of October 2025 |
Vivek Mehra | Independent Director | — | — |
Sushil Kumar Roongta | Independent Director | — | — |
Arun Seth | Independent Director | — | — |
Shirish Gundopant Belapure | Independent Director | — | — |
Ramakrishnan Arul | Independent Director | — | — |
Harsh Mahajan | Independent Director | — | — |
Shivpriya Nanda | Independent Director | — | Woman director |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Role |
|---|---|
Priyavrat Bhartia | Managing Director |
Arjun S. Bhartia | Joint Managing Director |
Arvind Chokhany | Group CFO, Whole-Time Director |
Ashish Mukkirwar | Chief Financial Officer (effective 23 May 2026) |
Shantanu Jha | Group Chief Human Resources Officer |
Dr Tushar Gupta | Head — Corporate Strategy |
Harsher Singh | CEO — Jubilant Radiopharma |
Chris Preti | CEO — CDMO Sterile Injectables (Jubilant HollisterStier) |
Kyle Ferguson | CEO — Allergy Immunotherapy |
Giuliano Perfetti | CEO — CRDMO, Jubilant Biosys |
Dr Jaidev Rajpal | CEO — Jubilant Generics |
Daniel J. O'Connor | President and CEO — Jubilant Therapeutics Inc. (effective 1 December 2025) |
Prakash Bisht | Executive Vice President — Group Accounts |
Surajit Pal | Head of Investor Relations |
Naresh Kapoor | Company Secretary and Compliance Officer |
Directors' Remuneration
| Executive | Salary (INR Mn) | Total compensation (INR Mn) | Salary share of total (%) |
|---|---|---|---|
Priyavrat Bhartia, Managing Director | 25.0 | 67.5 | 37.1 |
Arjun S. Bhartia, Joint Managing Director | 0.0 | 67.5 | 0.0 |
Arvind Chokhany, Group CFO and WTD | 0.0 | 44.8 | 0.0 |
Shareholding Trend
| Holder category | Sep 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
Promoter and promoter group (%) | 50.67 | 50.67 | 50.67 | 47.67 | 47.67 |
Foreign institutional investors (%) | 23.20 | 19.06 | 17.23 | 15.90 | 15.87 |
Domestic institutional investors (%) | 1.64 | 3.77 | 7.05 | 11.63 | 12.40 |
Public and non-institutional (%) | 23.89 | 25.91 | 24.48 | 24.25 | 23.50 |
Others including employee benefit trust (%) | 0.59 | 0.58 | 0.56 | 0.56 | 0.55 |
Number of shareholders | 89,376 | 92,264 | 96,526 | 86,347 | 82,703 |
Governance Detail
| Promoter entity | Holding (%) | Shares |
|---|---|---|
SPB Trustee Company Pvt Ltd | 20.52 | 32,686,161 |
HSB Trustee Company Pvt Ltd | 19.00 | 30,257,475 |
Miller Holdings Pte Ltd (foreign) | 3.28 | 5,230,455 |
MAV Management Advisors LLP | 3.15 | 5,011,400 |
Nikita Resources Private Limited | 2.20 | 3,504,540 |
Jubilant Enpro Private Limited | 1.33 | 2,116,000 |
Priyavrat Bhartia | 0.88 | 1,398,010 |
Hari Shanker Bhartia | 0.23 | 360,885 |
Shamit Bhartia | 0.08 | 129,245 |
Kavita Bhartia | 0.01 | 10,285 |
Major Shareholders
| Holder | Type | Holding (%) | Shares |
|---|---|---|---|
East Bridge Capital Master Fund I Ltd | FPI | 3.92 | 6,241,736 |
Government Pension Fund Global (Norges Bank) | FPI | 3.45 | 5,502,797 |
Estate of Late Mr Rakesh Jhunjhunwala | Public individual | 3.28 | 5,224,000 |
Rekha Jhunjhunwala | Public individual | 3.15 | 5,020,000 |
Quant Mutual Fund — Quant Small Cap Fund | Domestic MF | 1.92 | 3,059,145 |
SBI Life Insurance Co. Ltd | Domestic insurer | 1.39 | 2,219,866 |
Theleme India Master Fund Limited | FPI | 1.32 | 2,107,924 |
Abakkus Emerging Opportunities Fund-1 | AIF | 1.20 | 1,909,849 |
Investor Education and Protection Fund | Statutory | 1.25 | 1,994,498 |
Competitive Landscape
Competitor Detail
| Network | Radiopharmacies | SPECT capable | PET capable | Hospitals served |
|---|---|---|---|---|
Largest competitor (Cardinal Health) | 160+ | Yes | Yes | ~4,100 |
Jubilant Radiopharmacies | 45 | Yes | Yes | ~1,800 |
Competitor 3 | 41 | Yes | No | ~700 |
Competitor 4 | 31 | Yes | No | ~900 |
Competitor 5 | 42 | Yes | Yes | ~200 |
Competitor 6 | 14 | Yes | No | ~200 |
Competitor Detail (Annual)
| Metric | Jubilant Pharmova FY2026 |
|---|---|
Revenue (INR Cr) | 8,280 |
Revenue growth (%) | 14.5 |
EBITDA margin (%) | 15.9 |
Net profit margin (%) | 4.8 |
Return on capital employed (%) | 9.0 |
Recent Developments
--



